The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in XXXX with @entity706 .

@entity1 @entity706 @entity1349
UNASSIGNED: For @entity1 with diffuse large B cell lymphoma without the involvement of the CNS, the addition of rituximab to standard chemotherapy has significantly improved survival. In this single-center, retrospective analysis, a total of 81 @entity706 ( @entity706 ) @entity1 treated in our institution between 2000 and 2011 were included. Beside first-line chemotherapy with or without rituximab, we evaluated the impact of age ( <=/>60  years), autologous stem cell transplantation (ASCT +/-), and other factors upon @entity1349 ( @entity1349 ) and progression-free survival (PFS). In @entity1 treated with rituximab (n   =   27), 3-year @entity1349 was 77.8  % (95  % confidence interval (CI) 62-93  %). In contrast, in @entity1 treated without rituximab (n   =   52), 3-year @entity1349 was only 39.9  % (CI 27-53  %, Fig.  1). The difference in @entity1349 was significant in the univariate (p   =   0.002) as well as in the multivariate analysis (p   =   0.049, hazard ratio (HR)   =   0.248). @entity1  <=60  years of age (n   =   28) had a 3-year @entity1349 of 78.2  % (CI 63-94  %); in @entity1 >60  years (n   =   51), 3-year @entity1349 was 38.7  % (CI 25-52  %). @entity1 who received high-dose therapy and ASCT had a 3-year @entity1349 of 85.2  % (CI 72-99  %), and 65.1  % were alive up to the time of analysis (range 9-131  months). Without ASCT, median @entity1349 was only 16  months (CI 11-21) and 3-year @entity1349 was 35.2  % (CI 22-48  %). Age and ASCT were significantly associated with better @entity1349 in univariate (p   =   0.002 and p   <   0.001) as well in multivariate analysis (p   =   0.004, HR   =   0.023 and p   =   0.001, HR   =   0.014). Rituximab treatment, ASCT, and age are independent prognostic factors for @entity1349 in the first-line treatment of @entity706 .
